GlaxoSmithKline plc (GSK.L)


LSE - LSE Delayed Price. Currency in GBp
1,653.00+4.00 (+0.24%)
At close: 12:12 PM EDT
People also watch:
BP.LAZN.LRDSB.LVOD.LULVR.L
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1,649.50
Prev Close1,649.00
Bid1,650.00 x 175400
Ask1,655.00 x 417900
Day's Range1,643.50 - 1,654.83
52wk Range1,227.50 - 1,716.50
1y Target EstN/A
Market Cap80.1B
P/E Ratio (ttm)2,755.00
BetaN/A
Volume4,642,219
Avg Vol (3m)8,315,159
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • TheStreet.com18 hours ago

    5 Stocks to Sell Now Before It's Too Late

    These stocks could be toxic to your portfolio in the month ahead.

  • Financial Times2 days ago

    [$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience

    To most people who have encountered Emma Walmsley, her appointment this week as the next head of GlaxoSmithKline, the UK drugmaker, will probably come as little surprise. "She's ruthlessly ambitious," ...

  • Reuters3 days ago

    Hard to swallow: emerging markets get tougher for drugmakers

    Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building. A few years ago, the developing world was seen as a savior as patent after patent expired across the United States and Europe, but emerging market sales growth at the top drug firms slowed to less than two percent in the latest quarter. Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent.